The viral capping enzyme nsP1: A novel target for the inhibition of chikungunya virus infection

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Delang, L ^a   Li, C ^b,c   Tas, A ^d   Querat G ^e   Albulescu, I C ^d   De Burghgraeve, T ^a   Segura Guerrero, N A ^a   Gigante, A ^f   Piorkowski, G ^e   Decroly, E ^b,c   Jochmans, D ^a   Canard, B ^b,c   Snijder, E J ^d   Perez Perez M J ^f   Van Hemert, M J ^d   Coutard, B ^b,c   Leyssen, P ^a   Neyts, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CNRS   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Aix Marseille University IRD 190 Inserm 1207   (France)

^f INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PYRIMIDINONE DERIVATIVE; VIRAL PROTEIN;

ALPHAVIRUS INFECTION; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; CHIKUNGUNYA VIRUS; CHLOROCEBUS AETHIOPS; DRUG EFFECT; GENETICS; HORSE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; VERO CELL LINE; VIROLOGY;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; DRUG RESISTANCE, VIRAL; ENCEPHALOMYELITIS, EQUINE; HORSES; MOLECULAR STRUCTURE; PYRIMIDINONES; SMALL MOLECULE LIBRARIES; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84983428089     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31819     Document Type: Article

References (34)

1. Powers, A. M., et al. Evolutionary relationships, and systematics of the alphaviruses. J. Virol. 75, 10118-10131 (2001).
2. Chen, L. H., & Wilson, M. E. Dengue, and chikungunya in travelers. Current Opinion in Infectious Diseases 25, 523-529 (2012).
3. Tilston, N., Skelly, C., & Weinstein, P. Pan-European Chikungunya surveillance: designing risk stratified surveillance zones. Int. J. Health Geogr. 8, 61 (2009).
4. Leparc-Goffart, I., Nougairede, A., Cassadou, S., Prat, C., & De Lamballerie, X. Chikungunya in the Americas. The Lancet 383, 514 (2014).
5. Hoz, J. M. D. La, et al. Fatal cases of Chikungunya virus infection in Colombia: Diagnostic, and treatment challenges. J. Clin. Virol. 69, 27-29 (2015).
6. Torres, J. R., et al. Chikungunya fever: Atypical, and lethal cases in the Western hemisphere. IDCases 2, 6-10 (2015).
7. Singh, S. K., & Unni, S. K. Chikungunya virus: Host pathogen interaction. Rev. Med. Virol. 21, 78-88 (2011).
8. Schilte, C., et al. Chikungunya virus-Associated long-Term arthralgia: a 36-month prospective longitudinal study. PLoS Negl. Trop. Dis. 7, e2137 (2013).
9. Khan, M., Santhosh, S. R., Tiwari, M., Lakshmana Rao, P. V., & Parida, M. Assessment of in vitro prophylactic, and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells. J. Med. Virol. 82, 817-824 (2010).
10. Brighton, S. W. Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. South African Med. J. 66, 217-218 (1984).
11. De Lamballerie, X., et al. On chikungunya acute infection, and chloroquine treatment. Vector borne zoonotic Dis. 8, 837-839 (2008).
12. Delang, L., et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broadspectrum antiviral. J. Antimicrob. Chemother. 69, 2770-2784 (2014).
13. Abdelnabi, R., Neyts, J., & Delang, L. Towards antivirals against the chikungunya virus. Antiviral Res. 121, 59-68 (2015).
14. Gigante, A., et al. Identification of [1, 2, 3]triazolo[4, 5-d]pyrimidin-7(6H)-ones as novel inhibitors of Chikungunya virus replication. J. Med. Chem. 57, 4000-4008 (2014).
15. Salvador, B., Zhou, Y., Michault, A., Muench, M. O., & Simmons, G. Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines, and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393, 33-41 (2009).
16. Delogu, I., et al. In vitro antiviral activity of arbidol against Chikungunya virus, and characteristics of a selected resistant mutant. Antiviral Res. 90, 99-107 (2011).
17. Albulescu, I. C., Tas, A., Scholte, F. E. M., Snijder, E. J., & van Hemert, M. J. An in vitro assay to study chikungunya virus RNA synthesis, and the mode of action of inhibitors. J. Gen. Virol. 95, 2683-2692 (2014).
18. Li, C., et al. mRNA capping by Venezuelan Equine Encephalitis Virus nsP1: Functional characterization, and implication for antiviral research. J. Virol. 89, 8292-8303 (2015).
19. Scholte, F. E. M., et al. Characterization of synthetic Chikungunya viruses based on the consensus sequence of recent E1-226V isolates. PLoS One 8, e71047 (2013).
20. Decroly, E., Ferron, F., Lescar, J., & Canard, B. Conventional, and unconventional mechanisms for capping viral mRNA. Nat. Rev. Microbiol. 10, 51-65 (2012).
21. Ahola, T., Laakkonen, P., Vihinen, H., & Kaariainen, L. Critical residues of Semliki Forest virus RNA capping enzyme involved in methyltransferase, and guanylyltransferase-like activities. J. Virol. 71, 392-397 (1997).
22. Lin, H. Y., Yu, C. Y., Hsu, Y. H., & Meng, M. Functional analysis of the conserved histidine residue of Bamboo mosaic virus capping enzyme in the activity for the formation of the covalent enzyme-m7GMP intermediate. FEBS Lett. 586, 2326-2331 (2012).
23. Vasiljeva, L., Merits, A., Auvinen, P., & Kaariainen, L. Identification of a novel function of the Alphavirus capping apparatus. RNA 5'-Triphosphatase activity of Nsp2. J. Biol. Chem. 275, 17281-17287 (2000).
24. Karpe, Y. A., Aher, P. P., & Lole, K. S. NTPase, and 5'-RNA triphosphatase activities of chikungunya virus nsP2 protein. PLoS One 6, e22336 (2011).
25. DuBois, R. M., et al. Structural, and Biochemical Basis for Development of Influenza Virus Inhibitors Targeting the PA Endonuclease. PLoS Pathog. 8, e1002830 (2012).
26. Ferron, F., Decroly, E., Selisko, B., & Canard, B. The viral RNA capping machinery as a target for antiviral drugs. Antiviral Res. 96, 21-31 (2012).
27. Balzarini, J., De Clercq, E., Serafinowski, P., Dorland, E., & Harrap, K. R. Synthesis, and antiviral activity of some new S-Adenosyl-Lhomocysteine derivatives. J. Med. Chem. 35, 4576-4583 (1992).
28. Ahola, T., & Karlin, D. G. Sequence analysis reveals a conserved extension in the capping enzyme of the alphavirus supergroup, and a homologous domain in nodaviruses. Biol. Direct 10, 1-21 (2015).
29. Sokoloski, K. J., et al. Noncapped alphavirus genomic RNAs, and their role during infection. J. Virol. 89, 6080-6092 (2015).
30. Panning, M., Grywna, K., Van Esbroeck, M., Emmerich, P., & Drosten, C. Chikungunya fever in travelers returning to Europe from the Indian Ocean Region, 2006. Emerg. Infect. Dis. 14, 416-422 (2008).
31. Tan, L. Van, et al. Me Tri virus: A Semliki Forest virus strain from Vietnam? J. Gen. Virol. 89, 2132-2135 (2008).
32. Lavillette, D., et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J. Biol. Chem. 281, 3909-3917 (2006).
33. Scholte, F. E. M., et al. Stress granule components G3BP1, and G3BP2 play a proviral role early in Chikungunya virus replication. J. Virol. 89, 4457-4469 (2015).
34. Metz, S. W., et al. Functional processing, and secretion of Chikungunya virus E1, and E2 glycoproteins in insect cells. Virol. J. 8, 353 (2011).